Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In

 Latest News

Pharmerit conducted an analysis to estimate the incremental cost-effectiveness of hexaminolevulinate for patients diagnosed with non-muscle invasive bladder cancer (NMIBC) in Italy
Despite its rarity, anal cancer places a significant economic burden on the public purse and moreover resource pressures on the national health service.
We have enjoyed meeting you at the 17th European ISPOR conference in Amsterdam, November 2014. Hand-outs of the poster sessions are available on our ISPOR Amsterdam event page.
​Meet our team of experts at the ISOQOL 21st Annual Conference in Berlin, 15-18 October, 2014. We invite you to our exhibit, presentations, and workshop.
On September 18, 2014, Pharmerit and IPAM jointly hosted a successful workshop in Berlin.
Adalimumab is cost effective in treating Spanish patients with non-radiographic axial spondyloarthritis and elevated CRP and/or positive MRI.
In the first study examining pHF-W vs. CMF in an Asian country, Pharmerit, Nestlé Nutrition and affiliates found pHF-W to be a cost effective alternative for atopic dermatitis.
Guideline-recommended treatments for PHN are more effective vs. placebo. Additional evaluations for less common NeP conditions are required, despite published treatment guidelines.
Anastomotic leaks—one of the surgical complications following colorectal surgeries—are associated with significant economic burden in the United States, including significantly extended hospital stays and excess medical costs.
The risks of BSIs vary according to the type of parental nutrition provided. The safest approach, consisting of ready-to-use three-chamber bag (MCB), was also shown to be essentially cost neutral.
Contact Feel free to contact us if you have any questions